NCT02376608

Bioavailability of Omega-3 Food Supplement in Healthy Subjects

Pronovum - An Open-label, Randomized, Single-dose Study to Evaluate the Bioavailability of Omega-3 Food Supplements in Healthy Male and Female Subjects.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Pronova BioPharma · Industry
• Sex: —
• Age: —
• Healthy volunteers: Accepted

Summary

The study will evaluate the relative bioavailability of Pronovum PRF-037 and Pronovum PRF-041 with PronovaPure 150:150 EE EU and Eskimo-3 (500 mg omega-3 acid triglyceride containing 80 mg EPA and 50 mg DHA per gram oil) in healthy subjects.

Conditions

• Biological Availability

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Pronova Pure 150:500 EE EU	Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
DIETARY_SUPPLEMENT	Pronovum PRF-037	Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
DIETARY_SUPPLEMENT	Pronovum PRF-041	Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
DIETARY_SUPPLEMENT	Eskimo-3	Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period

Timeline

• Start date: 2014-08-01
• Primary completion: 2014-09-01
• Completion: 2014-09-01
• First posted: 2015-03-03
• Last updated: 2015-03-03

Locations

1 site across 1 country: United Kingdom